Abivax (CHIX:ABVXP) Net Income From Continuing Operations : €-147.74 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Abivax Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Abivax's net income from continuing operations for the six months ended in Dec. 2023 was €-126.56 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was €-147.74 Mil.

Abivax Net Income From Continuing Operations Historical Data

The historical data trend for Abivax's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax Net Income From Continuing Operations Chart

Abivax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-33.30

-38.01

-42.45

-60.74

-147.74

Abivax Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial															-25.56	-51.95	-8.79	-21.18	-126.56

Abivax Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-147.74 Mil.

Abivax (CHIX:ABVXP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (CHIX:ABVXp) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

ABVX:USA AAVXF:USA 0RA9:UK ABVX:France 2X1:Germany

Address

7-11 boulevard Haussmann, Paris, FRA, 75009

Website

https://www.abivax.com

Abivax SA is a France-based biotechnology company. It is focused on using antiviral technology platforms targeting the immune system to eliminate viral diseases. The antiviral and immunotherapeutic products that the group develops result from three technology platforms; a Modulation of RNA Biogenesis platform, an Immune stimulation platform, and a Polyclonal antibody platform. The Antiviral platform targets the formation of Ribonucleoprotein in the nucleus or the cytoplasm of the infected cell during viral infection, the Immune stimulation platform focuses on invariant natural killer agonists and the Polyclonal antibodies platform generates neutralizing antibodies against different viruses. Its current pipeline includes ABX464 for Ulcerative Colitis and ABX196 for Hepatocellular Carcinoma.

Abivax (CHIX:ABVXP) Headlines

No Headlines